Sugi Predict

Sugi Predict / Compounds / SCHEMBL489698

SCHEMBL489698

SCHEMBL489698

Fc1c(Cl)cccc1CBr

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PNMT P11086 2/20 0.41
▸ AKR1B1 P15121 1/20 0.40
▸ IDO1 P14902 4/20 0.38
▸ MPO P05164 1/20 0.38
▸ TAAR1 Q96RJ0 3/20 0.38
▸ HTT P42858 1/20 0.37
▸ CFD P00746 1/20 0.35
▸ P2RX7 Q99572 2/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP2A6 P11509 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29466762 1.00 PNMT (0.41) PNMTAKR1B1IDO1MPOTAAR1
SCHEMBL1051230 0.98 PNMT (0.40) PNMTAKR1B1IDO1MPOTAAR1
SCHEMBL18555551 0.98 PNMT (0.40) PNMTAKR1B1IDO1MPOTAAR1
SCHEMBL960397 0.83 GABRA1 (0.36) IDO1TAAR1
SCHEMBL22657687 0.83 TAAR1 (0.39) PNMTAKR1B1IDO1MPOTAAR1
SCHEMBL12373155 0.83 PNMT (0.39) PNMTAKR1B1IDO1MPOTAAR1
SCHEMBL29447850 0.83 TAAR1 (0.39) PNMTAKR1B1IDO1MPOTAAR1
SCHEMBL30031464 0.81 MEP1B (0.34) P2RX7
SCHEMBL80728 0.79 TAAR1 (0.37) PNMTAKR1B1IDO1MPOTAAR1
SCHEMBL3069271 0.79 PNMT (0.43) PNMTAKR1B1IDO1MPOTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146047-A1 MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-05-28 — — US disclosed
CN-122055361-A Fascin inhibitors 北京双鹤润创科技有限公司 2026-05-15 — — CN disclosed
EP-4720054-A1 FASCIN INHIBITORS Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) 2026-04-08 — — EP disclosed
US-20260092033-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2026-04-02 — — US disclosed
EP-4680611-A1 MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2026-01-21 — — EP disclosed
US-12528773-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS INC. (CA) 2026-01-20 — — US disclosed
US-20260007672-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2026-01-08 — — US disclosed
US-12491185-B2 Inhibitors of mPTP NRG THERAPEUTICS LTD (GB) 2025-12-09 — — US disclosed
EP-4652162-A1 INHIBITORS OF MPTP NRG Therapeutics LTD (GB) 2025-11-26 — — EP disclosed
US-20250346592-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION 2025-11-13 — — US disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 — — US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 — — US disclosed
CN-1202152-A Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency HOFFMANN LA ROCHE (CH) 1998-12-16 — — CN disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 — — EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 — — WO disclosed
US-5409943-A [(alkoxy)pyridinyl]amine compounds which are useful in the treatment of gastrointestinal disorders SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1995-04-25 — — US disclosed
EP-0625143-A1 PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1994-11-23 — — EP disclosed
WO-1993015055-A1 PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1993-08-05 — — WO disclosed
EP-0061907-B1 SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE BEECHAM GROUP PLC (GB) 1984-08-01 — — EP disclosed
EP-0061907-A1 Secondary amines, their preparation, pharmaceutical compositions containing them and their use BEECHAM GROUP PLC (GB) 1982-10-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528773-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, GAA PNMT 4179/4885AKR1B1 2133/4885IDO1 757/4885
US-12491185-B2 Inhibitors of mPTP PARK7, PINK1, SNCA PNMT 80/4885AKR1B1 1394/4885IDO1 225/4885
US-20260092033-A1 HETEROCYCLIC COMPOUND AND USE THEREOF HCRTR2, HCRTR1, MTNR1B PNMT 240/4885AKR1B1 2497/4885IDO1 808/4885
US-20260007672-A1 INHIBITORS OF MPTP PARK7, SNCA, CYC1 PNMT 1040/4885AKR1B1 294/4885IDO1 315/4885
US-20250346592-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI6, PADI2 PNMT 385/4885AKR1B1 606/4885IDO1 103/4885
US-20260146047-A1 MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF HCRTR2, HCRTR1, NPY1R PNMT 1603/4885AKR1B1 2268/4885IDO1 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.